P53 Invest — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

Valink Therapeuticsvalinktx.com inOct 2025

Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

Arne Scheu(Co-Founder & CEO)in Irsyad Khairil(Co-Founder & CTO)in

Co-investorsHoxton Ventures LongeVC Metaplanet Oxonian Ventures SynBioVen Ventac Partners +8 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.